Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation. - Wikidata - awgldk - TriplyDB

Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation.

Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation.

http://www.wikidata.org/entity/Q42129242

about

Treatment dilemmas of cetuximab combined with chemotherapy for metastatic colorectal cancer Reactive Oxygen Species-Mediated Mechanisms of Action of Targeted Cancer Therapy Cellular and molecular mechanisms for the synergistic cytotoxicity elicited by oxaliplatin and pemetrexed in colon cancer cell lines.High ERCC1 expression predicts cisplatin-based chemotherapy resistance and poor outcome in unresectable squamous cell carcinoma of head and neck in a betel-chewing area.ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting.KRAS mutational status affects oxaliplatin-based chemotherapy independently from basal mRNA ERCC-1 expression in metastatic colorectal cancer patients.ERCC1, defective mismatch repair status as predictive biomarkers of survival for stage III colon cancer patients receiving oxaliplatin-based adjuvant chemotherapy Role of Reactive Oxygen Species in the Abrogation of Oxaliplatin Activity by Cetuximab in Colorectal Cancer.Role of cetuximab in first-line treatment of metastatic colorectal cancer First-line targeted therapies in the treatment of metastatic colorectal cancer - role of cetuximab Oxaliplatin: a review of approved uses.Cetuximab in metastatic colorectal cancer.Optimizing treatment of metastatic colorectal cancer patients with anti-EGFR antibodies: overcoming the mechanisms of cancer cell resistance.Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer.ERCC1 Induction after Oxaliplatin Exposure May Depend on KRAS Mutational Status in Colorectal Cancer Cell Line: In Vitro Veritas.Preclinical emergence of vandetanib as a potent antitumour agent in mesothelioma: molecular mechanisms underlying its synergistic interaction with pemetrexed and carboplatin.Liver-directed chemotherapy of cetuximab and bevacizumab in combination with oxaliplatin is more effective to inhibit tumor growth of CC531 colorectal rat liver metastases than systemic chemotherapy Cetuximab enhances the activities of irinotecan on gastric cancer cell lines through downregulating the EGFR pathway upregulated by irinotecan.Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer.

P2860

Q26747335-F6D032F4-0673-4790-B613-EB83BB682AAC Q33862425-F6E369EC-8368-47A1-869D-B9E605270BB5 Q33914993-CE89C5D1-317E-4F65-9635-1E8792AA7E2E Q34769944-C60C1539-6E0C-48DE-802F-B9D6D1ACC7B6 Q35833376-CF6C95CC-1270-4F92-84CF-4C3838B962E3 Q36557853-2949A71A-BC60-4E42-A9F6-63EDE0757C55 Q36747418-8CD40705-4C85-41F1-8557-20A9369307CA Q36895532-C2B37FFF-A383-4391-8D42-67B5C2820C29 Q37708010-51A89B50-8709-4FDB-AC0A-52FD7D0D5DD4 Q37771245-52385F21-6FFD-42D5-95EF-A89FCFF68D8A Q37965616-9D23A58E-86EB-4C7C-9176-43C203FC4EF0 Q38010796-4AADEB52-38D9-48AB-9959-E130AE144FCA Q38071119-7A23B644-797B-4888-B7EF-F1022CA2DD77 Q38090584-58C53DE2-AC0D-4C58-BF27-F8DF3AB841E1 Q38923998-0944A8B7-2E97-46F1-B47F-5C93F29CD6A4 Q39463417-F55AC132-D583-44B0-85F0-5AFD8E23B8FF Q39579889-73B36EA0-DE38-4AA4-A622-615E334F957B Q39599249-0F91CB17-CCCA-4A1E-9DE4-D9E949153D43 Q47126394-17315A8E-F9C3-44C5-9A77-69BA44BA56B3

P2860

Cetuximab potentiates oxaliplatin cytotoxic effect through a defect in NER and DNA replication initiation.

http://www.wikidata.org/entity/Q42129242

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

Cetuximab potentiates oxalipla ...... nd DNA replication initiation.

@en

Cetuximab potentiates oxalipla ...... nd DNA replication initiation.

@nl

type

label

Cetuximab potentiates oxalipla ...... nd DNA replication initiation.

@en

Cetuximab potentiates oxalipla ...... nd DNA replication initiation.

@nl

prefLabel

Cetuximab potentiates oxalipla ...... nd DNA replication initiation.

@en

Cetuximab potentiates oxalipla ...... nd DNA replication initiation.

@nl

P1433

Q42129242-6DE5BC73-BCC9-4717-ADA8-E6D79C6620DF

P1476

Q42129242-1C406A04-4D3A-4B3D-AB39-3D4412A0AF76

P2093

Q42129242-3D94251B-2D19-463E-B446-7D4ABC246FD8

Q42129242-575EAE2D-DDB7-4963-A0ED-B2BC23AC1C43

Q42129242-6B8B48B6-6CC0-4356-A33A-B658E4E1AB09

Q42129242-7CDE3FEF-D3A4-41FA-B8AF-CE2BD033B7D6

Q42129242-8104674D-78E2-4035-9783-98111A8CFA45

Q42129242-8DA5A0FC-B458-4EA7-8156-958611EFA5B4

Q42129242-92853967-E20A-4C0F-9F11-853A3C1C7547

Q42129242-B1C73C80-CC82-4722-8BF8-26F4B707D421

Q42129242-F98392AB-CB71-42B3-833C-3EAB54C41B5F

P2860

Q42129242-0195C93C-6FB8-4B5D-874D-392F4F0637CD

Q42129242-0F6AE9A8-5D9A-489A-94BB-20D7B077497E

Q42129242-18E93433-EA43-4DB1-98B9-F842D065E793

Q42129242-389B99BB-0CBF-4C61-BC82-ADC187E4C7ED

Q42129242-46BA71BC-6B7D-4931-8D53-BEAE9FDEA901

Q42129242-71586089-0FD7-4BC9-9BC5-59349D9A6F5B

Q42129242-7467A20A-379E-4F3E-9217-C22D7A0C58C4

Q42129242-883201BA-EB34-40D3-A40F-DB2494AFDC2C

Q42129242-89D36247-4118-495D-8B9D-C975E4AE68E7

Q42129242-9973A243-DC1B-43AE-BF59-71274C3D2B39

P2888

Q42129242-841F5407-D1D0-4861-A51D-D54754A711B3

P304

Q42129242-CDA5934C-C781-41EF-8AC9-426215AEF859

P31

Q42129242-6ED91617-28F8-48C2-A4E7-DDB64A0FAF98

P356

Q42129242-F2C1CE89-1403-483C-A718-9AF62DD95CC8

P407

Q42129242-3313D02E-724E-45F4-A51C-D73231A7737D

P433

Q42129242-853E0A10-5E30-4B9D-8B66-0CF763B98116

P478

Q42129242-0D42D78A-5D85-492E-A2EA-438DFEB96876

P577

Q42129242-4E03C5B5-6DAF-44B5-88ED-11F0E246616E

P5875

Q42129242-EA136B9B-8912-4E79-BD7C-17A1BEE4BB2E

P698

Q42129242-6D7061B7-497A-4621-B1E8-0FD848FFFA3E

P921

Q42129242-16EA9B7D-C4C6-45C6-9053-DD60A383B43E

Q42129242-9083EE23-A054-4C83-ACBB-FA900EAF1C7F

P932

Q42129242-61704924-4B9B-4E45-BA5E-4C1220DD1EA8

P356

P1433

British Journal of Cancer

P1476

Cetuximab potentiates oxalipla ...... nd DNA replication initiation.

@en

P2093

B C Allal

http://www.w3.org/2001/XMLSchema#string

C Cazaux

http://www.w3.org/2001/XMLSchema#string

D Balin-Gauthier

http://www.w3.org/2001/XMLSchema#string

J-P Delord

http://www.w3.org/2001/XMLSchema#string

J-S Hoffman

http://www.w3.org/2001/XMLSchema#string

M-J Pillaire

http://www.w3.org/2001/XMLSchema#string

P Canal

http://www.w3.org/2001/XMLSchema#string

P Rochaix

http://www.w3.org/2001/XMLSchema#string

R Bugat

http://www.w3.org/2001/XMLSchema#string

P2860

Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes

Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.

Glutathione S-transferases. The first enzymatic step in mercapturic acid formation

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

Cellular determinants of oxaliplatin sensitivity in colon cancer cell lines.

Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents.

The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities.

Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.

Cellular and molecular pharmacology of oxaliplatin.

Molecular mechanisms of platinum resistance: still searching for the Achilles' heel.

P2888

P304

120-128

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/SJ.BJC.6604134

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

98

http://www.w3.org/2001/XMLSchema#string

P577

2008-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5667397

http://www.w3.org/2001/XMLSchema#string

P698

18182978

http://www.w3.org/2001/XMLSchema#string

P921

P932

2359709

http://www.w3.org/2001/XMLSchema#string